[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jiangmen Central Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":66},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100639094","phase-2-low-dose-thoracic-radiotherapy-followed-by-adebrelimab-plus-chemotherapy-and-then-sequential-maintenance-therapy-with-adebrelimab-for-extensive-stage-small-cell-lung-cancer-100639094",false,"NCT07583550","Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer","Efficacy and Safety of Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy and Sequential Adebrelimab Maintenance Therapy for Extensive-stage Small Cell Lung Cancer: A Prospective, Multicenter Phase II Study","Inclusion Criteria:\n\n1. Age ≥18 years and ≤75 years;\n2. Histologically or cytologically confirmed SCLC;\n3. No malignant pleural effusion or pericardial effusion;\n4. No prior history of thoracic radiotherapy or thoracic surgery;\n5. No prior systemic anti-tumor therapy;\n6. ECOG performance status 0-2, with a life expectancy of ≥12 weeks;\n7. At least one measurable lesion per RECIST 1.1 criteria;\n8. No history of interstitial pneumonia;\n9. No history of immune-related pneumonitis;\n10. No history of autoimmune diseases;\n11. No history of significant active pulmonary infection;\n12. No use of corticosteroid therapy within 14 days prior to enrollment;\n13. No Grade ≥3 hematologic toxicity or hepatic\u002Frenal impairment;\n14. No brainstem metastases and no significant neurological symptoms;\n15. For subjects with coexisting HBV\u002FHCV infection, hepatic impairment ≤ Grade 1 after prior active antiviral therapy;\n16. All subjects have provided written informed consent;\n\nExclusion Criteria:\n\n1. Presence of interstitial pneumonia or infectious fever prior to treatment;\n2. Comorbid autoimmune diseases or long-term oral corticosteroid use (including those who received oral corticosteroids within 14 days prior to treatment);\n3. Prior history of thoracic radiotherapy or thoracic surgery;\n4. Presence of Grade ≥3 hematologic toxicity or hepatic\u002Frenal impairment;\n5. Hypersensitivity to adebrelimab;\n6. Significant respiratory symptoms that preclude tolerance to radiotherapy;\n7. Active hepatitis B or C infection, currently on antiviral therapy, and with liver function impairment of Grade 2 or above;\n8. Presence of pleural effusion or pericardial effusion;","ALL","18 Years","75 Years",{"count":20,"type":21},43,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This study is a multicenter, prospective investigation aiming to evaluate the efficacy and safety of low-dose radiotherapy (15Gy\u002F1.5 Gy bid × 10 fractions) combined with 4-6 cycles of systemic chemotherapy concurrently with Adebrelimab, followed by Adebrelimab maintenance therapy for up to two years, in subjects with extensive-stage small cell lung cancer (ES-SCLC). Additionally, immunohistochemical detection of the expression levels of four key transcriptional proteins-YAP1, NEUROD1, ASCL1, and POU2F3-will be performed to guide the molecular subtyping of SCLC. Based on these findings, we will explore the differential therapeutic outcomes of this regimen across distinct molecular subtypes (A\u002FN\u002FP\u002FY\u002FI\u002FAN\u002FQN), with the goal of identifying the subject population most likely to benefit from this treatment modality, thereby optimizing clinical decision-making.",[27,28],"Lung","Radiotherapy","NOT_YET_RECRUITING","2026-07-20",{"date":32,"type":33},"2026-07-22","ACTUAL",{"date":35,"type":21},"2026-07-21",{"date":37,"type":21},"2028-01-01",{"name":39,"class":40},"Jiangmen Central Hospital","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":51,"conditions":52,"keywords":55,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":65,"locationsCount":4},"100630048","phase-2-furmonertinib-plus-radiotherapy-for-egfr-nsclc-with-pleural-effusion-100630048","NCT07482605","Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion","A Prospective, Multicenter Study on the Safety and Efficacy of Furmonertinib Combined With Local Chest Radiotherapy in EGFR+ Non-small Cell Lung Adenocarcinoma Patients With Malignant Pleural Effusion","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Histologically or cytologically confirmed advanced lung adenocarcinoma.\n3. Unlimited number of metastatic lesions, but with involvement of no more than 3 organs.\n4. Previously untreated, clinical stage IV disease per AJCC\u002FUICC 9th edition.\n5. Presence of pleural effusion as indicated by chest CT or ultrasound; cytological confirmation of malignant cells in the pleural effusion is preferred. If malignant cells are not detected in the pleural effusion, chest CT with contrast or whole-body PET\u002FCT must demonstrate unequivocal pleural nodular metastases.\n6. After 8-10 weeks of furmonertinib therapy with or without therapeutic thoracentesis, the overall radiographic response is assessed as effective (CR + PR + SD), and malignant pleural effusion is adequately controlled (defined as no pleural effusion or only minimal pleural effusion on ultrasound or chest CT: maximum depth \\\u003C 3 cm, estimated volume \\\u003C 500 mL). Concurrent minimal pericardial effusion is permissible (defined as maximum diastolic width \\\u003C 1 cm on echocardiography, estimated volume \\\u003C 100 mL).\n7. No prior thoracic radiotherapy.\n8. Positive for EGFR-sensitive mutations (exon 19 deletion or exon 21 L858R).\n9. No prior systemic anticancer therapy.\n10. ECOG performance status 0-2, with a life expectancy of ≥ 12 weeks.\n11. At least one measurable lesion per RECIST 1.1.\n12. Adequate bone marrow function to tolerate anticancer treatment: WBC ≥ 3 × 10⁹\u002FL, Hb ≥ 80 g\u002FL, PLT ≥ 75 × 10⁹\u002FL, and absolute neutrophil count (NEUT) ≥ 1.5 × 10⁹\u002FL.\n13. Essentially normal hepatic and renal function:\n\n    1. Serum creatinine ≤ 1.5 × upper limit of normal (ULN) or creatinine clearance (CrCl) ≥ 50 mL\u002Fmin;\n    2. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN (≤ 5 × ULN is acceptable in patients with liver metastases);\n    3. Total bilirubin (TBIL) ≤ 1.5 × ULN;\n    4. Albumin ≥ 30 g\u002FL and prealbumin ≥ 150 g\u002FL.\n14. Asymptomatic brain metastases.\n15. Written informed consent obtained from all subjects.\n\nExclusion Criteria:\n\n1. Pre-existing interstitial lung disease (ILD) or infectious fever prior to treatment.\n2. Radiographic progression (PD) after 8-10 weeks of TKI therapy, or development of grade ≥ 2 ILD.\n3. Concurrent autoimmune disease requiring long-term oral corticosteroid therapy.\n4. Severe anemia.\n5. Known hypersensitivity to furmonertinib.\n6. Significant respiratory symptoms (e.g., chest tightness, cough) that preclude tolerance to radiotherapy.\n7. Active hepatitis B or C virus infection with concomitant grade \\> 2 hepatic impairment. Patients may be considered eligible if liver function recovers to grade 1 after active hepatoprotective therapy and antiviral treatment.\n8. Poorly controlled or continuously progressive pleural effusion after 8-10 weeks of furmonertinib therapy.\n9. Symptomatic brain metastases.",{"count":49,"type":21},63,[24],"This study is designed as a prospective, multi-center investigation to explore the efficacy and safety of furmonertinib combined with upfront thoracic radiotherapy with or without metastatic lesion radiotherapy in subjects with EGFR-mutant NSCLC and malignant pleural effusion (MPE), aiming to provide additional evidence-based medical support for optimizing the management of NSCLC-MPE subjects. In addition, peripheral blood ctDNA next-generation sequencing (NGS) will be performed at two time points-before the first furmonertinib treatment and one month after the completion of thoracic radiotherapy-to identify subpopulations most likely to benefit from this therapeutic approach and to elucidate resistance mechanisms specific to the radiotherapy-plus-furmonertinib combination, ultimately facilitating more personalized care for these subjects.",[53,54],"Lung Cancer (NSCLC)","Malignant Pleural Effusions (Mpe)- Pleurodesis",[56,28,57,58],"Furmonertinib","EGFR mutation","Lung adenocarcinoma","2026-07-16",{"date":61,"type":33},"2026-07-17",{"date":63,"type":21},"2026-07-01",{"date":37,"type":21},{"name":39,"class":40},""]